InspireMD Receives Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award

Recognized for Successful Introduction of New and Innovative Products, with Emphasis on Quality and Customer Value

BOSTON, InspireMD, Inc. ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), today announced that its MGuard Prime^™ Embolic Protection System integrated with MicroNet^™ has received the Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award.  Through active market research efforts, Frost & Sullivan's global team of analysts and consultants recognize the successful introduction of new and innovative products, with emphasis on quality and customer value.

Frost & Sullivan Senior Research Analyst Parthasarathy Raghava stated, "While significant improvements in clinical outcomes of percutaneous coronary interventions have been achieved with the use of coronary stents, distal embolization remains a major complication, resulting in poorer functional recovery and adverse outcomes.  However, our market research activities noted that InspireMD's MGuard Prime^™ with MicroNet^™addresses this challenge with its innovative design to trap and seal thrombus and plaque against the vessel wall, helping prevent distal embolization, while optimizing flow and ensuring excellent deliverability.  We are pleased to confer this Innovation Award on InspireMD."

MGuard Prime™ is a Cobalt Chromium stent wrapped in MicroNet™. MicroNet™ is a bio-stable mesh woven from a single strand of 20 micrometers Polyethylene Terephthalate.

Alan Milinazzo, CEO of InspireMD commented, "We are honored to receive the Frost & Sullivan 2015 European Coronary Stent New Product Innovation Award, supporting our efforts to develop and commercialize embolic protection stent systems that improve patient outcomes by leveraging our proprietary MicroNet^™technology."

"We look forward to further enhancements to our coronary platform, including strategic partnerships in the development of a drug eluting stent system."  Mr. Milinazzo continued, "We are also in active development of new applications for our MicroNet^™ technology, in addition to MGuard^™ and our carotid system, CGuard^™, bringing innovation to treatment programs in the neurovascular and peripheral markets."

Source: InspireMD, Inc.